Radiotherapy for the Management of Non-Oncologic Diseases: How to Treat and Why It Works
Although radiotherapy is a well-established treatment modality for both solid and liquid tumors, its utility in the management of benign diseases remains poorly elucidated. In general, oncologists and non-oncologic specialists in the U.S.
Category
  • Functional/Nonmalignant RT
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Brain Metastases Radiotherapy While Mitigating Radionecrosis and Neurotoxicity in a Community Setting
There are many strategies for managing brain mets with radiotherapy.
Category
  • Central Nervous System
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
How to Treat Benign Diseases - Experiences of the German Cooperative Group on Benign Diseases (GCG-BD)
The activity gives an overview of irradiation of benign diseases. The worldwide unique evidence-based S2-guideline of the German Society for Radiation Oncology (DEGRO) that has been translated into English is also presented.
Category
  • Functional/Nonmalignant RT
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Gynecologic Tumor Board–Case-Based Discussion of the Molecular & Treatment Approach Updates for the Management of Endometrial, Vulvar & Cervical Cancers
There have been many recent studies that further differentiate gynecologic cancers and their management relating to pathologic features, such as molecular status.
Category
  • Gynecologic
  • Immunotherapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Advances in Breast Cancer Management: Early-Stage Disease, Post-Neoadjuvant Radiation Therapy and IMRT for Breast Cancer Treatment in a Community Setting
There are multiple new developments in the treatment of breast cancer patients with radiation therapy, as well as ongoing developments in the use of breast IMRT. Practicing clinicians need to stay informed to improve outcomes among breast cancer patients.  
Category
  • Breast
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Management of Unfavorable Intermediate-Risk Prostate Cancer: Role of SBRT, Brachytherapy and Androgen Deprivation
Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or
Category
  • SBRT
  • Brachytherapy
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Management of Small Cell Neuroendocrine Tumors of the Genitourinary Tract
Molecular diagnostics are rapidly evolving, leading to increased identification of previously 'rare' clinical entities.
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Implementation of a Prostate SBRT Program in the Community Setting
Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups.
Category
  • SBRT
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Moving Beyond Auditory Speech: Improving Equity for Patients and Providers with Diverse Communication Needs
Despite the prevalence of hearing loss or deafness, many physicians are unfamiliar with how best to support patients and colleagues with diverse communication needs.
Category
  • Patient Safety
  • General RO
  • Health Policy/Informatics
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $49.00
The Hidden Risks of Artificial Intelligence (AI): Biases and Disparities in the Global Development and Deployment of AI for Cancer Care
Artificial intelligence (AI) and machine learning (ML) are beginning to have a dramatic impact on the field of medicine in the domains of clinical decision making, radiation planning and interactions between patients and their medical teams.
Category
  • Patient Safety
  • Health Policy/Informatics
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00

Pages